Theralase(R) Successfully Destroys Lung Cancer
Theralase(R) Successfully Destroys Lung Cancer
TORONTO, ON / ACCESSWIRE / June 6, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF) is a clinical stage pharmaceutical company that is dedicated to the research and development of light and/or radiation activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it's lead compound, RuvidarTM, combined with transferrin to form the compound Rutherrin, has been proven effective preclinically in the destruction of Non-Small Cell Lung Cancer ("NSCLC").
Theralase Technologies公司(簡稱Theralase或公司)(TSXV: TLT)(OTCQB: TLTFF)是一家臨床階段的製藥公司,致力於研究和開發用於安全、有效地摧毀各種癌症、細菌和病毒的光和/或輻射活化小分子。它很高興地宣佈,其領先化合物Ruvidar與轉鐵蛋白結合形成複合物Rutherrin,在臨床前證明在非小細胞肺癌(NSCLC)的破壞中是有效的。此款超便攜式投影儀使用了最新的 Android TV 界面,而且遙控器還內置了 Google AssistantTM 功能,用戶可以非常方便地使用它。如圖1所示,肺腫瘤比正常肺組織更長時間保持了Rutherrin的濃度(p> 0.01),從而大大提高了Rutherrin對肺癌的選擇性。
Theralase recently completed experiments in NSCLC, using a Lewis Lung Cancer ("LLC1") orthotopic model. In this model, mouse lungs are subjected to lung cancer cells, which induces these mice to develop very aggressive, fast growing and metastatic lung tumours.
Theralase最近在NSCLC中完成了實驗,使用Lewis肺癌(LLC1)成體模型。在這個模型中,將小鼠肺暴露於肺癌細胞,使這些小鼠產生非常侵略性、快速增長和轉移性的肺腫瘤。
As shown in Figure 1, lung tumours retained Rutherrin longer than normal lung tissues (p> 0.01), leading to a substantially improved selectivity of Rutherrin to target lung cancer.
如圖1所示,肺癌組織比正常肺組織更長時間保留了Rutherrin(p>0.01),從而大幅提高了Rutherrin對肺癌的選擇性。
Figure 1: Rutherrin concentration in normal and tumour lung after single 3mg/kg Intra Venous ("IV') injection
圖1:單次3mg / kg靜脈注射後正常和腫瘤肺中的Rutherrin濃度
Theralase has demonstrated that all animals treated with x-ray activated Rutherrin are currently alive; unfortunately, this is not the case for mice that received x-ray treatment only.
Theralase已經證明,所有接受X射線激活的Rutherrin治療的動物目前都還活着;不幸的是,僅接受X射線治療的小鼠並非如此。
In addition, the mice treated with x-ray activated Rutherrin have demonstrated up to a 4-fold slower tumour progression, based on the Magnetic Resonance Imaging ("MRI") assessment of tumour volumes.
此外,接受X射線激活的Rutherrin治療的小鼠經MRI評估其腫瘤體積,其腫瘤進展速度最多緩慢了4倍。
Figure 2: Tumour volume analysis in mice after tumour inoculation and treatment with either radiation only or combined treatment of Rutherrin and radiation treatment
圖2:經腫瘤接種和放療或聯合Rutherrin和放療治療後,小鼠的腫瘤體積分析
As shown in Figure 2, there is a significant delay in tumour progression in mice treated with x-ray activated Rutherrin versus with radiation alone (p> 0.001). In fact, in mice treated with x-ray activated Rutherrin, the tumour is notably regressing / being destroyed over time.
如圖2所示,在X射線激活的Rutherrin治療小鼠中,腫瘤進展延遲明顯,遠優於僅接受放療的小鼠(p> 0.001)。 實際上,在接受X射線激活的Rutherrin治療的小鼠中,腫瘤隨着時間明顯萎縮/被摧毀。
Dr. Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer of Theralase stated, "Between 30 to 50% of patients with any form of cancer today receive radiotherapy at some point during their treatment. The results presented today represent Theralase's commitment to unlocking the inherent value of the patented x-ray activated Rutherrin Anti-Cancer Therapy ("ACT") platform for the benefit of the millions of patients, who are diagnosed with difficult to treat cancers at various disease stages and risk factors. Patients diagnosed with cancers, such as: Glio Blastoma Multiforme ("GBM") or NSCLC are faced with limited treatment options, with this new research hopes to solve. In several, well established, orthotopic animal models; specifically: rat GBM brain cancer and mouse LLC1 lung cancer, Theralase has demonstrated a significant destruction of cancer cells (p>0.001) and an inhibition in their regrowth. In addition, the Theralase preclinical research team is researching the application for x-ray activated Rutherrin to be IV administered for numerous other cancers; including: pancreatic cancer, prostate cancer, kidney cancer and colorectal cancer.
Theralase的首席科學家Dr. Arkady Mandel萬.D.,Ph.D.,D.Sc.表示:"今天癌症治療的任何形式患者中有30%至50%在某個時候接受放療。今天所呈現的結果反映了Theralase致力於爲被診斷爲存在疾病的各種疾病階段和風險因素的數百萬病人解鎖基於專利的x射線激活的Rutherrin抗癌療法("ACT")平台的內在價值。被診斷爲存在難以治療的癌症,如:Glio Blastoma Multiforme("GBM")或NSCLC的患者面臨治療選擇有限的困境,這項新研究希望爲其提供幫助。在多個經過充分驗證的原位動物模型中,特別是:大鼠GBm腦癌和小鼠LLC1肺癌,Theralase已經展示了對癌細胞的顯著破壞(p>0.001)和抑制其重新生長的實驗證據。此外,Theralase的臨床前研究團隊正在研究x射線激活的Rutherrin能夠靜脈注射用於其他許多癌症,包括:胰腺癌,前列腺癌,腎癌和結直腸癌。
Roger DuMoulin-White, B.Sc., P.Eng., Pro.Dir., President and Chief Executive Officer of Theralase stated "Pending the successful completion of the Good Laboratory Practice ("GLP") toxicology program, Theralase intends to commence a Phase Ia dose escalating clinical study in 4Q2024 for patients diagnosed with GBM and NSCLC, to determine the appropriate clinical dose of Rutherrin to be administered from a safety perspective; including: toxicity and tumour localization. This research may expand to include: pancreatic cancer, prostate cancer, kidney cancer and colorectal cancer, based on capitalization. Following successful completion of Phase Ia, a Phase Ib study will be commenced to determine patient efficacy, using x-ray activated Rutherrin. Pending the successful completion of the Phase Ia/Ib clinical study, Theralase plans to commence a Phase II clinical study in Canada and the United States focused on enrolling and treating patients diagnosed with GBM and NSCLC, which as previously mention may expand to include patients diagnosed with pancreatic cancer, prostate cancer, kidney cancer and colorectal cancer, subject to capitalization.
Theralase總裁兼首席執行官Roger DuMoulin-White B.Sc.,P.Eng.,Pro.Dir表示:“在成功完成了良好實驗室規範(GLP)毒理學項目後,Theralase計劃在2024年第四季度開始進行一項Ia逐劑量臨床研究,以確定用於治療GBM和NSCLC患者的Rutherrin的適當臨床劑量,從安全的角度,包括毒性和腫瘤定位。根據投資規模,此研究可擴展至包括胰腺癌、前列腺癌、腎腺癌和結直腸癌等。在成功完成Ia/Ib臨床研究後,Theralase計劃啓動一項II期臨床研究,重點招募和治療診斷爲GBM和NSCLC的患者,如前面提到的可能擴展至診斷爲胰腺癌、前列腺癌、腎腺癌和結直腸癌的患者,取決於投資。
About Lung Cancer:
關於肺癌:肺癌是男性≥40歲和女性≥60歲的癌症死亡主因,致死率高於任何其他男性或女性的主導性癌症。新診斷的肺癌病例中,佔80%至85%的人患的是NSCLC。目前,NSCLC患者接受三種傳統治療方法的治療,包括:手術、化療和放療。在後一種情況下,患者接受腫瘤的局部放療,用大劑量的X射線或伽馬射線分數分割施加多周。這種照射,通常與化療聯合使用,可能導致更或多或少持久的緩解;然而,對於經常在疾病的晚期被診斷出來的NSCLC患者而言,預後不佳,NSCLC仍然是全球癌症死亡的主要原因。
Lung cancer is the leading cause of cancer mortality in men aged ≥40 years and women aged ≥60 years, causing more deaths than any other dominant cancer of men or women. The largest demographic (80 to 85%) of newly diagnosed cases of lung cancer are NSCLC. Currently, patients with NSCLC are treated with the three conventional therapeutic methods; including: surgery, chemotherapy and radiation. In the latter case, patients are subjected to localized irradiations of the tumor with large doses of x-ray or gamma rays, which are divided into smaller fractions applied over several weeks. Such irradiations, often combined with chemotherapy, can lead to more or less durable remissions; however, the prognosis for NSCLC patients, which are often diagnosed at an advanced stage of the disease, remains poor and NSCLC continues to be the leading cause of cancer death worldwide.
關於Theralase Technologies Inc.:Theralase是一家臨床階段的製藥公司,致力於研究和開發光和/或輻射活化的小分子化合物及其相關藥物製劑和激活它們的光系統,其主要目標是在摧毀各種癌症、細菌和病毒方面發揮功效,而次要目標是確保安全性。
About Theralase Technologies Inc.:
有關信息,請訪問http://www.theralase.com和www.sedar.com。
Theralase is a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.
前瞻性聲明:本新聞稿包含適用加拿大證券法的"前瞻性聲明"。此類聲明包括但不限於公司就Photo Dynamic Compounds及其藥物製劑提出的發展計劃。這些聲明可能會通過使用“可能”、“應該”、“將”、“預計”、“相信”、“計劃”、“期望”、“估計”、“潛在”等表達方式來識別,包括與公司管理層對未來研究、開發和商業運作的期望,臨床研究和監管審批有關的聲明。
Additional information is available at and
這些聲明涉及重大風險、不確定性和假設,包括公司能否籌集資金並獲得監管審批以及成功地完成NMIBC Phase II臨床研究,並實施其發展計劃。其他風險包括:公司能否成功商業化其藥物製劑,該公司的藥物製劑在其臨床研究中檢測到的疾病中可能無效,公司未能遵守與第三方的許可協議的條款,因此失去在其業務中使用關鍵知識產權的權利,公司保護其知識產權的能力以及提交、接受審批的時間和成功程度等風險。很多決定實際結果的因素都超出了公司的能力和預測範圍。
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
TSX創業公司交易所及其監管服務提供方(該術語定義在TSX創業公司政策中)不對此發佈的充分性或準確性承擔任何責任。
Forward Looking Statements:
前瞻性陳述:
This news release contains "forward-looking statements" within the meaning of applicable Canadian securities laws. Such statements include; but are not limited to statements regarding the Company's proposed development plans with respect to Photo Dynamic Compounds and their drug formulations. Forward looking statements may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of Company's management for future research, development and commercialization of the Company's Photo Dynamic Compounds and their drug formulations, preclinical research, clinical studies and regulatory approvals.
讀者不應過度依賴這些前瞻性聲明,因爲此類前瞻性聲明並不能保證後續的表現。這樣的情況可以是因已知和未知的風險、不確定性和其他因素而導致公司的實際結果或未來事件與前瞻性聲明所表達的結果不符。
These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete a Phase II NMIBC clinical study in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its drug formulations, the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or may not be available at all, the risk that the Company's drug formulations may not be effective against the diseases tested in its clinical studies, the risk that the Company's fails to comply with the term of license agreements with third parties and as a result loses the right to use key intellectual property in its business, the Company's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.
這些聲明涉及重大風險、不確定性和假設,包括公司資助並獲得監管批准,以及按時完成第二期NMIBC臨床研究並實施其發展計劃的能力。其他風險包括:公司成功將其藥物配方商業化的能力,以有利於公司的商業條款可用性或根本不可用的足夠資本獲得訪問的風險,公司藥物配方可能對其臨床研究中測試的疾病無效的風險,公司未能遵守與第三方許可協議的條款,從而失去在業務中使用關鍵知識產權的權利,公司保護其知識產權的能力,以及提交、接受和批准監管申請的時間和成功。決定實際結果的許多因素都超出了公司的控制或預測範圍。
Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate as such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements.
讀者不應過度依賴這些前瞻性陳述,因爲它們並不保證未來業績。無法保證前瞻性陳述將證明準確,因爲這些前瞻性陳述涉及已知和未知的風險、不確定性和其他因素,這些因素可能導致實際結果或未來事件與前瞻性陳述存在實質性不同。
Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.
儘管新聞稿中的前瞻性陳述是基於管理層目前認爲合理的假設,但公司不能保證實際結果、業績或成就與這些前瞻性陳述一致。
All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements.
所有前瞻性陳述均截至本日,並可能發生變化。 除法律要求外,公司不承擔更新此類聲明的義務。
For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies.
如需了解有關公司的投資者信息,請隨時聯繫投資者查詢- Theralase Technologies.
For More Information:
更多信息:
1.866.THE.LASE (843-5273)
416.699.LASE (5273)
1.866.THE.LASE(843-5273)
416.699.LASE(5273)
Kristina Hachey, CPA
Chief Financial Officer
X 224
khachey@theralase.com
Kristina Hachey,特許公認會計師
致富金融(臨時代碼)
X 224
khachey@theralase.com
SOURCE: Theralase Technologies Inc.
來源:Theralase Technologies Inc.